Vertex cystic fibrosis drug misses trial goal, helps some

(Reuters) - Vertex Pharmaceuticals Inc's Kalydeco cystic fibrosis drug failed to meet the main goal of a late-stage study aimed at expanding its use into patients with a specific gene mutation associated with the rare, life-threatening lung disease, the company said on Thursday.
Source: Reuters: Health - Category: Consumer Health News Tags: healthNews Source Type: news